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Abstract
Aims The study objective was to investigate the safety and tolerability of up-titration to high doses of taspoglutide, a once-
weeklyhumanglucagon-likepeptide-1analogue,insubjectswithType 2diabetesinadequatelycontrolledonmetforminalone.
Methods In this double-blind phase II trial, subjects were randomized to placebo or taspoglutide (20 mg; three separate
groups)administeredonceweeklybysubcutaneousinjectionfor4 weeks.Thiswasfollowedbydosemaintenanceat20 mg,or
t i t r a t i o nt o3 0m g( 2 0⁄30) or 40 mg (20⁄40) once weekly with matched placebo for an additional 4 weeks. Subjects were
monitored for adverse events (AEs) throughout the study and 4-week follow-up.
Results One hundred and twenty-nine subjects were randomized and treated [mean age 57 years, mean baseline glycated
haemoglobin (HbA1c), 7.9%]. The most frequently reported AEs were nausea and vomiting. The number of patients reporting
gastrointestinal AEs did not increase following titration to higher doses of taspoglutide or when continuing the initial 20 mg
regimen.Three subjectswerewithdrawn fromthestudyasaresult ofgastrointestinalAEs(onebeforeandtwoaftertitrationto
higherdoses).Althoughnotdesignedtoinvestigateefﬁcacy,improvementinglycaemiccontrolwasobservedinallactivearmsof
the study. The proportion of subjects achieving HbA1c < 7.0% after 8 weeks of treatment was 72, 53 and 70% in the 20⁄20-,
20⁄30- and 20⁄40-mg arms, respectively, vs. 19% for placebo.
Conclusions Taspoglutide was safe, well tolerated at high doses and efﬁcacious for lowering HbA1c. Up-titration of dose was
not associated with a worsening AE proﬁle.
Diabet. Med. 27, 556–562 (2010)
Keywords clinical studies, drug treatment, glucagon-like peptide 1, new drugs, Type 2 diabetes
Abbreviations ACE, Angiotensin-converting enzyme inhibitors; AE, adverse event; ancova, analysis of covariance; GI,
gastrointestinal; GLP-1, glucagon-like peptide; HbA1c, glycated haemoglobin; ITT, intent-to-treat; LS, least squares; s.c.,
subcutaneously; Type 2 DM, Type 2 diabetes mellitus
Introduction
Taspoglutide is an analogue of the human incretin hormone
glucagon-like peptide 1 (GLP-1) that is currently in phase III
clinical development for treatment of Type 2 diabetes mellitus
(Type 2 DM). Taspoglutide is designed to make therapeutic use
of the glucoregulatory properties of GLP-1, which enhances
glucose-dependent insulin secretion, suppresses inappropriately
elevatedglucagonsecretion,slowsgastric emptying,andreduces
food intake [1–3]. Taspoglutide contains aminoisobutyric acid
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These modiﬁcations confer a 12-fold increase in stability over
GLP-1 when incubated in rat serum and render the compound
resistanttodipeptidylpeptidase-4(DPP-4)mediatedinactivation
[4]. Taspoglutide shows high binding afﬁnity to the human
GLP-1 receptor and assessment of its relative activity on cyclic
adenosine monophosphate stimulation in cells expressing the
GLP-1 receptor suggests that it is fully active [4]. Taspoglutide
improved glucose tolerance, normalized postprandial glucose,
improved glycaemic control and insulin sensitivity, and reduced
excess body weight in a rat model of Type 2 DM [5]. Its
resistance to proteolytic degradation and a zinc-based sustained-
release formulation confer an extended half-life and allow for
once-weeklysubcutaneousadministration(s.c.).Anearlyclinical
trial showed that a single administration of taspoglutide 8 or
30 mg to patients with Type 2 DM reduced fasting and
postprandial plasma glucose levels, stimulated insulin secretion
and reduced glucagon levels [6]. Moreover, reductions in
glycated haemoglobin (HbA1c), fructosamine and body weight
were observed in a dose-ﬁnding phase II study [7]. In the latter
study, mixed meal tests before and after treatment in a subset of
patients revealed that taspoglutide signiﬁcantly improved
pancreatic B-cell function, as measured by improvements in
insulin secretion rates and B-cell glucose sensitivity [8].
The primary aim of the current study was to investigate the
safety and tolerability of up-titration to high doses of
taspoglutide in patients with Type 2 DM and to determine





This study was a randomized, double-blind, placebo-
controlled phase II trial conducted at 27 sites in six
countries (Australia, France, Germany, Mexico, Peru and
the USA) between April 2007 and October 2007. The study
consisted of a double-blind 8-week treatment period with an
additional 4-week follow-up. It was planned to enrol
approximately 120 subjects into the study, assigned
randomly and equally to each of the treatment groups. This
sample size was determined by practical considerations rather
than formal calculations. Subjects on stable metformin
monotherapy were randomized to receive placebo s.c. once
weekly for 8 weeks, or 20 mg taspoglutide s.c. once weekly
for 4 weeks, followed by 4 weeks of 20 mg once weekly
(20⁄20), or titration up to 30 mg once-weekly (20⁄30) or
40 mg once-weekly (20⁄40) taspoglutide (Fig. 1). The doses
and titration scheme were selected using modelling and
simulation. The predicted drug exposure was adequately
tolerated in patients with Type 2 DM uncontrolled by
metformin in a previous trial where taspoglutide was
infused at doses up to 800 lg⁄day (F. Hoffmann-La Roche;
d a t ao nﬁ l e ) .
Acommonclinicaltrialprotocolwasapprovedforeachsiteby
an institutional review board. All subjects provided written
informed consent before participation and the study was
conducted in accordance with the principles described in the
Declaration of Helsinki, including all amendments through the
1996 South Africa revision (World Medical Association
Declaration of Helsinki) [9].
Randomization was implemented via a central system using a
stratiﬁed randomization procedure based on disease severity
(HbA1c <8 . 0 % o r ‡ 8.0%) to avoid imbalances between
treatment groups.
The primary endpoint of this study was GI tolerability, which
was assessed by comparing the number of subjects who
withdrew from the study because of GI adverse events (AEs)
in the active treatment groups with those in the placebo group.
Secondary endpoints included changes in fasting plasma
glucose, HbA1c and body weight, and pharmacokinetic
parameters.
FIGURE 1 Study design.
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The study population comprised men and post-menopausal or
surgically sterilized women aged 18–75 years with Type 2 DM,
treatedwithastabledailydoseofmetforminmonotherapyforat
least 3 months before screening. The dosage of metformin was
not adjusted during the study. Key inclusion criteria at screening
were HbA1c between 7.0% and 9.5% (inclusive), fasting plasma
glucose > 7.0 mmol⁄l and £ 13.3 mmol⁄l, body mass index
(BMI) > 25.0 kg⁄m
2and £ 45.0 kg⁄m
2, and weight less than or
equal to 10% for at least 3 months before screening.
Subjects with serious co-morbidities or abnormalities in
laboratory tests were excluded from the study, as were those
who had previously been treated with GLP-1 receptor agonists
(including GLP-1 itself) at any time, or with other glucose-
lowering medications (apart from metformin) or weight-loss
medications within 12 or 6 weeks, respectively. The use ofother
glucose-loweringmedications,glucose-loweringherbalremedies
or weight-loss medications during the study was not permitted
(i.e. required withdrawal from blinded study drug). ACE,
thiazide diuretics, thyroid hormones and⁄or lipid-lowering
medications were permitted but only with dose(s) stable for at
least 6 weeks prior to screening.
Study procedures
Eligible subjects who had given prior written informed
consent attended clinic visits weekly during the 8-week
treatment period, beginning on the day of ﬁrst treatment
(day 0⁄week 0), and during the 4-week follow-up period. At
each visit, vital signs and body weight were monitored, AEs
were recorded and fasting blood samples were taken. A 12-
lead electrocardiogram was conducted at weeks 0, 4, 8 and
11. Study drug was administered before breakfast during the
clinic visits in weeks 0–7. Subjects were asked to follow their
pre-study diet and exercise plan and metformin regimen
throughout the study. Subjects reported to the study site for
weekly visits. At each visit the lyophilized peptide was
reconstituted at the study site with the diluent (zinc chloride
solution). Subjects in the placebo group received 0.9% sodium
chloride (NaCl). Study medication was administered by
personnel not involved with the preparation of study drug
to maintain the blinding and injected s.c. in the abdomen in a
different site each time, according to a given scheme.
AEswerecategorizedas:(i)‘mild’iftransientwithdiscomfort,
but no disruption of normal daily activity; (ii) ‘moderate’ if
sufﬁcient discomfort to reduce or affect daily activity; or (iii)
‘severe’ if the discomfort rendered the subject unable to work or
performnormaldailyactivity.AwithdrawalruleforGIAEswas
implemented: ‘if severe nausea and⁄or vomiting requiring
therapy persist up to 24 h before the next scheduled
administration of the drug, the subject should be withdrawn
from the study.’
Standard laboratory assessments (haematology and
biochemistry) were conducted weekly. Fasting plasma glucose
was measured weekly and HbA1c was measured at weeks 0, 4,
and 8. Population pharmacokinetics were assessed using sparse
sampling. Central laboratories (Covance: Sydney, Australia;
Singapore; Geneva, Switzerland; Harrogate, UK; Indianapolis,
IN, USA) were used to measure all laboratory parameters
including drug concentrations of taspoglutide; the latter
were measured using a liquid chromatography⁄tandem mass




one dose of randomized study drug (the safety population). AEs
were categorized according to preferred terms in the Medical
Dictionary for Regulatory Activities (MedDRA), version 10.1
(Maintenance and Support Services Organization; Chantilly,
VA, USA). Descriptive statistics were used to report the safety
results. Data on secondary endpoints were analysed for the
intent-to-treat (ITT) population (all subjects who were
randomized to the study, received study drug and had a valid
baseline and at least one post-baseline HbA1c measurement),
using the last observation carried forward for dropouts. Data
were evaluated using analysis of covariance (ancova)t o
determine the least squares (LS) means of change from
baseline. The ancova model included treatment as the ﬁxed
effect term and baseline as the covariate.
Results
Subject demographics and disposition
One hundred and thirty-three subjects were randomized. Four
subjects (one from each of the treatment groups) did not receive
any study drug; therefore, the safety population consisted of 129
subjects (Fig. 1). The ITT population comprised 125 subjects.
The safety population was well balanced across the treatment
groups in terms of key demographic characteristics (Table 1).
During the study, many subjects received common medications
for cardiovascular risk factors; most frequently, statins (22%),
ACE inhibitors (21%) and ﬁbrates (5%). No subjects reported
using glucose-lowering medications other than metformin and
taspoglutide.
Safety and tolerability
No subject was withdrawn from the study because he⁄she met
thecriterionforwithdrawalasaresultofGIAEsasdeﬁnedinthe
study protocol; however, three out of 129 subjects were
withdrawn because of GI AEs at the request of the investigator.
Two of these subjects were in the 20⁄30-mg arm (dyspepsia,
vomiting) and one was in the 20⁄40-mg arm (upper abdominal
pain).Overall,16subjectswithdrewprematurelyfromthestudy;
one from the placebo arm, three from the 20⁄20-mg arm and six
each from the 20⁄30- and 20⁄40-mg arms. Seven of these
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describedabove;onefromtheplaceboarm(cardiacarrhythmia),
two from the 20⁄30-mg arm (the cases of dyspepsia, vomiting
described above) and four from the 20⁄40-mg arm (the case of
upper abdominal pain described above, and cases of ventricular
extrasystoles, contusion or hypoglycaemia).
The most commonly reported AEs were GI signs and
symptoms (Table 2). Nausea was most prevalent after the ﬁrst
and second weekly administrations, decreasing with subsequent
injections (Fig. 2). Of the subjects who reported nausea, most
reported it as mild to moderate in severity and in most cases the
nausea resolved spontaneously. A similar, temporal relationship
of vomiting in terms of duration and severity was also reported
(data not shown). Overall, the number of subjects who reported
GI AEs decreased over time and did not increase following
titration to the higher doses (30 or 40 mg). The number of
subjects who reported GI AEs was 16 (48%) before titration vs.
12 (41%) after titration in the 20⁄30-mg arm, and 12 (38%)
beforetitrationvs.10(36%)aftertitrationinthe20⁄40-mgarm.
WhileareductioninthenumberofsubjectsreportingGIAEswas
observed in all groups between the ﬁrst and second 4-week
treatment periods, the greatest reduction was seen in subjects
whoremainedonthe20-mgdoseoftaspoglutidethroughoutthe
8-week study period, with a decrease of approximately 48%
[from 17 (53%) to 9 (30%)].
Two serious AEs were reported in the study; cardiac
arrhythmia in a subject given placebo and the suspicion of
recurrence of prostate cancer in a subject in the 20⁄40
taspoglutide arm. Both events were considered by the
investigators to be unrelated to the study drug. No safety issues
with regard to vital signs, electrocardiogram or laboratory
analysis were identiﬁed during this trial. Injection site reactions
were observed in 13%, 69%, 52% and 59% of subjects in the
placebo, 20⁄20-, 20⁄30- and 20⁄40-mg groups, respectively;
thesewereconsideredmildormoderate,withnoseverereactions
reported.Mostofthesereactionswereindurationsthatappeared
soon after treatment administration and subsequently resolved
spontaneously. These local reactions were not usually
accompanied by any signs or symptoms of acute response; in
manycases,thereactionshadnotbeennoticedbythesubjectsbut
were reported by the investigators who had been instructed to
actively check every injection site at each visit.




20 mg once weekly
n =3 2
20⁄30 mg once weekly
n =3 3
20⁄40 mg once weekly
n =3 2
Male⁄female, n (%) 13⁄19 (41⁄59) 15⁄17 (47⁄53) 15⁄18 (45⁄55) 13⁄19 (41⁄59)
Age (years) 56  25 7  25 5  26 0  2
Weight (kg) 92.9  3.5 89.8  3.8 88.3  3.0 90.2  3.9
BMI (kg⁄m
2) 33.2  1.0 33.3  0.9 31.6  1.0 31.5  0.9
Duration of diabetes (years) 7  16  18  17  1
HbA1c (%) 7.8  0.1 8.0  0.1 8.0  0.1 7.8  0.1
Fasting glucose (mmol⁄l) 9.4  0.3 9.4  0.3 8.9  0.3 8.9  0.3
Data are mean  standard error.
BMI, body mass index; HbA1c, glycated haemoglobin.
Table 2 Most frequently reported adverse events (safety population, n = 129)*





20 mg once weekly
n =3 2
20⁄30 mg once weekly
n =3 3
20⁄40 mg once weekly
n =3 2
Nausea 4 (13) 12 (38) 17 (52) 11 (34)
Headache 4 (13) 5 (16) 2 (6) 3 (9)
Diarrhoea 3 (9) 4 (13) 7 (21) 3 (9)
Fatigue 1 (3) 3 (9) 4 (12) 1 (3)
Vomiting 0 4 (13) 9 (27) 4 (13)
Dyspepsia 0 6 (19) 5 (15) 5 (16)
Abdominal distension 0 3 (9) 4 (12) 1 (3)
*Adverse events that began during study treatment and occurred in ‡ 10% of subjects in any treatment group.
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glycaemia during the study: one in the placebo arm, one in the
20⁄20 arm, three in the 20⁄30 arm and two in the 20⁄40 arm of
the study. All subjects had recorded their blood glucose values at
the time of the event and only one of these events was
accompanied by blood glucose concentrations £ 2.8 mmol⁄l
(value = 2.8 mmol⁄l in a patient allocated to the 20⁄30-mg
arm). The blood glucose values recorded at the time of the
episodesinotherﬁvesubjectsrangedfrom3.3to5.7 mmol⁄l.No
severe episodes of hypoglycaemia were reported.
Pharmacokinetics and pharmacodynamics
Exposure to taspoglutide appeared dose proportional and time
dependent(Fig. 3)andafter8 weeksoftreatmentmediantrough
plasma concentration values were 44.4, 84.2 and 109.7 pmol⁄l
at 20⁄20, 20⁄30 and 20⁄40 mg once weekly, respectively.
ReductionsinHbA1cwereobservedinalltaspoglutide-treated
arms of the study (Fig. 4). At week 8, the changes from baseline
in HbA1c were )1.2  0.1, )0.9  0.1 and )1.2  0.1% in the
20⁄20-, 20⁄30- and 20⁄40-mg arms, respectively [LS
FIGURE 2 The number of subjects with nausea; mild⁄moderate (white) or
severe(black)overthe8-weekstudyperiodinthe:A,placebo;B,20⁄20 mg;
C, 20⁄30 mg; and D, 20⁄40 mg once-weekly taspoglutide arms (safety
population).
FIGURE 3 Plasma concentration (mean  standard error) of taspoglutide in groups receiving subcutaneous administration of 20⁄20 mg once weekly
(whitecircles),20⁄30 mgonceweekly(blackcircles)or20⁄40 mgonceweekly(blacksquares).Allgroupsreceived20 mgonceweeklyuntilweek 3.Theﬁrst
doses of 30 or 40 mg once weekly were administered at week 4. Pre-dose (trough) concentrations are shown for weeks 0–7; the insets show post-dose
concentrations for the ﬁrst 10 h after treatment at weeks 0, 4, and 7.
FIGURE 4 Glycated haemoglobin (HbA1c) (%) (last observation carried
forward) over time. Placebo (white); 20⁄20 mg taspoglutide (diagonal
shade);20⁄30 mgtaspoglutide(checkered);20⁄40 mgtaspoglutide(black).
Intent-to-treat population; least squares mean + standard error.
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(P < 0.0001 in all groups vs. the placebo group). Moreover, the
percentage of subjects achieving HbA1c < 7.0% was 72%
(20⁄20-mg group), 53% (20⁄30 mg) and 70% (20⁄40 mg) in
the taspoglutide arms vs. 19% in the placebo arm. Additionally,
the percentage of subjects achieving HbA1c < 6.5% was 41%
(20⁄20 mg), 21% (20⁄30 mg) and 37% (20⁄40 mg) in the
taspoglutide arms vs. none in the placebo arm. Fasting plasma
glucose was reduced (Fig. 5), with LS mean changes from
baselinetoweek 8of–2.3  0.3 mmol⁄l(20⁄20,P <0 . 0 0 0 1v s .
placebo), )1.6  0.3 mmol⁄l( 2 0 ⁄30, P = 0.007 vs. placebo)
and )2.2  0.3 mmol⁄l( 2 0⁄40, P < 0.0001 vs. placebo) in the
active study arms. By comparison over the same time period, in
subjects randomized to receive placebo, fasting plasma glucose
levels fell by 0.6  0.3 mmol⁄l.
Body weight decreased progressively in all groups throughout
the 8-week treatment period. Changes from baseline (LS
mean  se)w e r e)2.1  0.4 kg in the 20⁄20 group (P =0 . 7 7
vs. placebo), )3.0  0.3 kg in the 20⁄30 group (P =0 . 0 3v s .
placebo) and )2.7  0.4 kg in the 20⁄40 group (P =0 . 1 7v s .
placebo) compared with )2.0  0.3 kg in the placebo group.
Discussion
The main objective of this phase II study was to assess the safety
andtolerabilityofdosesoftaspoglutideupto30and40 mgonce
weekly, when administered following 20 mg once weekly for
4 weeks to subjects treated with stable doses of metformin
monotherapy. The major ﬁnding was that titration to higher
doses of taspoglutide following 4 weeks of 20 mg once weekly
was not associated with a deterioration of GI tolerability.
As expected froma GLP-1 receptor agonist, early human data
documented that transient nausea and vomiting were the most
commonly reported AEs following administration of
taspoglutide [6]. However, previous studies have demonstrated
for native GLP-1 and for other drugs in this class that gradual
dose escalation may help to mitigate the recognized GI side




remained on a dose of 20 mg taspoglutide throughout the study.
This ﬁnding is consistent with studies of other GLP-1 receptor
agonists, and with the expectation that the risk of nausea and
vomiting decreases with continued drug exposure [11,12]. The
pharmacokinetic analyses indicated that subjects who titrated to
higher doses (30 or 40 mg of taspoglutide) had proportionally
higherplasmalevelsofdrugthanthoseremainingon20 mgonce
weekly. Signiﬁcantly, no subjects withdrew from the study
because of nausea. The overall low occurrence of withdrawals
becauseofGIAEs,andthetimingofthesewithdrawals,supports
the study hypothesis that titration with taspoglutide is feasible
well beyond 20 mg.
Whilethisstudywasnotspeciﬁcallypoweredtoassessefﬁcacy,
taspoglutide 20 mg once weekly led to a statistically signiﬁcant
1.2% reduction in HbA1c after 8 weeks of treatment.
Furthermore, this dose enabled 72% of subjects to attain the
current American Diabetes Association and European
Association for the Study of Diabetes target HbA1c of < 7.0%
[13] from a baseline of 7.8–8.0%, with no signiﬁcant
hypoglycaemic episodes. Interpretation of the glycaemic data is
limited by the fact that the total treatment period was only
8 weeks, and that, as planned per protocol, the majority of
subjects received the highest dose of their assigned regimen for
only 4 weeks, an insufﬁcient duration of treatment to assess
maximal HbA1c reduction. Nonetheless, these ﬁndings suggest
rapidglycaemicefﬁcacyintermsofreductionofbothHbA1cand
fasting plasma glucose.
It is recognized that treatment with some commonly available
diabetes drugs is associated with weight gain [14], a distinct
disadvantage in a patient population in whom controlling body
weight is important to ameliorate the risk of diabetes
complications. Despite the short treatment duration of the
current study,there was a reduction in body weight in all groups
studied, including placebo, with an apparent trend towards
greaterweightlossinthe20⁄30-and20⁄40-mggroups.Thisisin
line with previous observations of another human GLP-1
analogue that higher doses than necessary for glucose control
still further reduce body weight, pointing to a rightward-shift in
the dose–response relationship for appetite control [15].
The development of GLP-1 receptor agonists has been an
important advance in the ﬁeld of diabetes medicine [16]. These
new therapies offer multiple improvements over existing drugs
with an emphasis on providing optimal glycaemic control;
however, currently approved GLP-1 receptor agonists are
administered daily or twice daily. Clearly, there is still a
requirement for compounds that are efﬁcacious and safe, but
also convenient to administer. Taspoglutide was developed with







































FIGURE 5 Fasting plasma glucose (FPG) concentrations change from
baseline (last observation carried forward) over time. Placebo (white
triangles); 20⁄20 mg taspoglutide (black squares); 20⁄30 mg taspoglutide
(white circles); 20⁄40 mg taspoglutide (black circles). Intent-to-treat
population; least squares mean  standard error.
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human once-weekly GLP-1 analogue, provides rapid glycaemic
improvement with a favourable safety and tolerability proﬁle.
Although not yet studied in comparative clinical trials, the GI
side-effect proﬁle observed in this study appears to be similar to
other GLP-1 receptor agonists. Additionally, this study conﬁrms
that dose titration and⁄or maintenance on the 20-mg dose of
taspoglutidewasnotassociatedwithanincreasedincidenceofGI
AEs. Although the short duration of the trial does not allow
deﬁnitive conclusions, the results support the hypothesis that
maximal efﬁcacy is achieved with a 20-mg dose. Indeed up-
titration of taspoglutide to 30 or 40 mg, although safe, was
devoid of any additional therapeutic effect. Further studies are
warranted and have commenced with the 20-mg once-weekly
dose of taspoglutide to gain a better understanding of the long-
term efﬁcacy and tolerability proﬁle.
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